Frontlight ResearchEarly access
CompletedPhase 1
A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin
Key facts
- Who runs it
- Cinclus Pharma Holding AB
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 12 people enrolled
- Started
- 11 Nov 2025
- Ended
- 22 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Drug Drug Interaction
- Record updated
- 27 February 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Willing and able to give written informed consent for participation in the trial
- Healthy male or female participant aged 18 to 64 years, inclusive
- Body mass index (BMI) ≥ 18.5 and ≤ 30.0 kg/m2 at the time of the screening visit
- Medically healthy participant without abnormal clinically significant medical history, physical findings, vital signs, ECG and laboratory values at the time of the screening visit, as judged by the Investigator
- Prospective participants, as well as their partners, must agree to the contraception requirements described in exclusion criteria 1 and 2
Who cannot take part
- Female participants of childbearing potential (defined as all participants physiologically capable of becoming pregnant) unless they agree to use one of the following highly effective methods of contraception (failure rate of <1%) from 2 weeks prior to the first dose until the end-of-trial visit:; Sterilization of a male partner, defined as vasectomy, at least six months prior to screening; Intra-uterine device (non-hormonal or copper IUD); Double-barrier methods of contraception, i.e., condoms in combination with occlusive cap with contraceptive gel
- Male participants with a partner of childbearing potential, unless they agree to use one of the following methods of contraception from two weeks prior to the first dose until the end-of-trial visit:; Vasectomy at least six months prior to screening; Condoms. Female partners of childbearing potential must then agree to concurrently use a highly effective method of contraception
- Positive result for H.pylori antibodies at the time of the screening visit
- History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial, or influence the results or the participant's ability to participate in the trial
- Any clinically significant illness, medical/surgical procedure or trauma within four weeks of the first administration of IMP
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an open, single arm, single-center Phase I trial designed to evaluate the effect of seven days repeated oral doses of linaprazan glurate on the pharmacokinetics (PK) of repeated doses of amoxicillin in healthy male and female participants
The group in the trial
- Linaprazan glurateTreatment being tested
Oral administration for seven (7) days.
Treatment: Drug Drug Interaction
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open, Single Arm, Single-center, Phase 1 Trial Investigating the Effect of 7-days-repeated Administration of Linaprazan Glurate on the Pharmacokinetics of Repeated Doses of Amoxicillin in Healthy Participants
- Record updated
- 27 February 2026